Aventis Pharma S.A., et al. v. Hospira, Inc., C. A. No.07-721-GMS, September 27, 2010.
Sleet, C. J. The court makes post-trial findings of fact and conclusions of law as follows: (A) claims 2 and 10 of the '561 patent are invalid due to indefiniteness; (B) all asserted claims of the patents-in-suit are invalid due to obviousness; (C) the asserted claims are unenforceable due to inequitable conduct; (D) the asserted claims are not invalid due to double patenting; (E) the defendants' proposed products infringe asserted claims 2, 5, and 10 of the '561 patent and claim 33 of the '512 patent; and (F) each of the parties Rule 52(c) motions are granted in part and denied in part.
Continue Reading...